"When Dave deBronkart was diagnosed with advanced kidney cancer in 2007, he learned about a treatment called high-dose interleukin-2 (IL-2) that fires up the body’s immune system to fight the disease. The response rate was not great — tumours shrank in only about 15% of patients. And as many as 4% of people died from the treatment. But some of those who responded survived for years or even decades."
Editor's note: IL-2 is an immunotherapy drug, meaning that it boosts a patient's own immune system to fight cancer. It and other new immunotherapies are showing promise for patients across many different cancer types.